products and services

diversion analytics

Product diversion reduces the bottom line and exposes patients to mishandled, counterfeit, and other dangerous products

Pharmaceutical product diversion creates a double cost to pharmaceutical manufacturers. Revenue is lost when downstream distributors take advantage of low-cost markets, redistribution, and price increases. Multiple product movements and inventory shifting also create the opportunity for unscrupulous entities to enter the marketplace, inserting foreign, mishandled, and even counterfeit products into the supply chain. The growing threat of bad products adds an additional risk to the manufacturer’s reputation and sales. But a proactive effort to detect diversion helps manufacturers get ahead and stay ahead of the risk.

A data-based approach

IntegriChain’s Enriched Channel Sales™ leverages manufacturer data to detect points of exposure to diversion within the U.S. market. By combining syndicated sales data, IntegriChain can assess diversion exposure from foreign sources of products. These analytics provide the first comprehensive proactive ability to detect potential by geographical region, product, or even at an individual account.

Benefits of transparency

Reduce price speculation. Locate inventories of product that do not appear in 852 data, and may erode margins.
Detect class-of-trade bleed. Stop ineligible customers from receiving price advantaged products.
Detect diversion. Find foreign product entering the U.S. market.
Professional advice. IntegriChain's professional services enable manufacturers to achieve faster and more comprehensive and custom-tailored benefits from Diversion Analytics.
No software required. IntegriChain services require no incremental investment in software or hardware, maximizing efficiency and minimizing cost.

With IntegriChain analytics, diversion is no longer a reaction to past events. Now you can proactively gain control of the entire supply chain and improve the bottom line through reduced distribution related costs.